FOLLOWING ADJUVANT TRASTUZUMAB-BASED THERAPY NERLYNX is your next step to further
reduce the risk of recurrence* IN EARLY-STAGE HER2+ BREAST CANCER1

See all efficacy results 2, †, †

DOSING AND ADMINISTRATION GUIDE

Learn about dose modifications, antidiarrheal prophylaxis, and drug interactions with NERLYNX.

Download

Patient Support

Puma Patient Lynx provides ongoing services for patients prescribed or taking NERLYNX, including a free 3-month supply of antidiarrheals.§

Learn more

Quick links

Full Prescribing Information Puma Patient Lynx
Enrollment Form
Specialty Pharmacy List

Select IMPORTANT SAFETY INFORMATION

The most common adverse reactions (>5%) were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, weight decreased and urinary tract infection.

Please see additional IMPORTANT SAFETY INFORMATION below.

HER2: human epidermal growth factor receptor 2; HR+: hormone receptor-positive

*Recurrence is defined as an invasive disease event or death.

95% of the HR+ study population received concurrent endocrine therapy.

Results of ExteNET are supported by an exploratory analysis of 5-year follow-up with 74.5% (2117/2840) of patients reconsented.4

§Not valid for prescriptions purchased under Medicaid, Medicare, TRICARE, or similar federal or state programs or for patients who are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees.

IMPORTANT SAFETY INFORMATION

NERLYNX® (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS: The most common adverse reactions (>5%) were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, weight decreased and urinary tract infection.

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) and www.NERLYNX.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

For Full Prescribing Information, please click here.